WHO Drug Information Vol. 18, No. 2, 2004 - World Health ...

More documents

Recommendations

Info

WHO Drug Information Vol 18, No. 2, 2004 Inosine R. 9-ß-D-ribofuranosyl-1,9-dihydro-6H-purin-6-one; C 10 H 12 N 4 O 5 . A commercially available reagent of suitable grade. Description. A crystalline powder. Dihydrate, long rectangular plates from water, melting point = 90 ˚C. Anhydrous needles from 80% alcohol, decomposition 218 ˚C (rapid heating). Solubility. Sparingly soluble in water. Specific optical rotation. (c = 0.9 in H 2 O with c = concentration by volume, g/100 ml after optical rotation only). Silica gel for chromatography, octadecylsilyl, base-deactivated Consultation Document A very finely divided silica gel, pretreated before the bonding of octadecylsilyl groups to minimize the interaction with basic components. 147
New ATC level codes (other than 5th level): 148 WHO Drug Information Vol 18, No. 2, 2004 ATC/DDD Classification (Final) The following final anatomical therapeutic chemical (ATC) classifications and defined daily doses (DDDs) were agreed at a meeting of the WHO International Working Group for Drug Statistics Methodology which took place in October 2003. They came into force on 1 March 2004 and will be included in the January 2005 issue of the ATC index. The inclusion of a substance in the lists does not imply any recommendation of use in medicine or pharmacy. The WHO Collaborating Centre for Drug Statistics Methodology can be contacted through e-mail: whocc@nmd.no. ATC level INN/Common name ATC code New ATC 5th level codes: New DDDs: Other hormone antagonists and related agents L02BX abarelix L02BX01 aprepitant A04AD12 aripiprazole N05AX12 buprenorphine, combinations N07BC51 cetuximab L01XC06 enfuvirtide J05AX07 enoxolone D03AX10 flutrimazole G01AF18 fosamprenavir J05AE07 ibuprofen C01EB16 insulin glulisine A10AB06 methazolamide S01EC05 micafungin J02AX05 olmesartan medoxomil C09CA08 sacrosidase A16AB06 strontium ranelate M05BX03 temoporfin L01XD05 undecylenic acid, combinations D01AE54 INN/common name DDD Unit Adm.R ATC code adalimumab 2.9 mg P L04AA17 apraclonidine 0.3 ml S01EA03 clofoctol 1.5 g R J01XX03 colistin 3 MU Inhal. sol. J01XB01 enfuvirtide 0.18 g P J05AX07 everolimus 1.5 mg O L04AA18
Page 1 and 2: WHO DRUG INFORMATION V O L U M E 18
Page 3 and 4: World Health Organization 112 WHO D
Page 5 and 6: Aspects of Quality Assurance cities
Page 7 and 8: Aspects of Quality Assurance 3. Wor
Page 9 and 10: Safety and Efficacy Issues 12 hours
Page 11 and 12: Safety and Efficacy Issues 8. Gogta
Page 13 and 14: Safety and Efficacy Issues exists r
Page 15 and 16: International Nonproprietary Names
Page 17 and 18: International Nonproprietary Names
Page 19 and 20: Regulatory and Safety Action should
Page 21 and 22: Regulatory and Safety Action be rev
Page 23 and 24: Regulatory and Safety Action one ye
Page 25 and 26: Safety of Medicines to copy, combin
Page 27 and 28: Safety of Medicines feiting include
Page 29 and 30: Current Topics 138 WHO Drug Informa
Page 31 and 32: Current Topics 2. Kosek, M., Bern,
Page 33 and 34: Current Topics Rapid TB diagnostic
Page 35 and 36: Consultation Document Description:
Page 37: Consultation Document Assay 146 WHO
Page 41 and 42: 150 WHO Drug Information Vol 18, No
Page 43 and 44: ATC/DDD Classification New DDDs: 15
Page 45 and 46: Recent Publications and Sources of
Page 47 and 48: Proposed INN: List 91 WHO Drug Info
Page 89 and 90:
Proposed INN: List 91 WHO Drug Info
Page 91:
Proposed INN: List 91 WHO Drug Info
show all

WHO Drug Information Vol. 18, No. 2, 2004 - World Health ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?